Donate For Public and Patients Store Search

S005 - Follicular Rescue in Scarring Alopecias: Treating to Halt Disease Progression and Grow Hair

Friday, March 1; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Define the clinical, dermatoscopic, and pathology clues to follicular rescue in scarring hair loss
  • Describe the appropriate cases of cicatricial alopecia to consider for optimal treatment outcome
  • Demonstrate the success of medical, laser, and surgical treatments in appropriately selected cases of scarring alopecia

Description

This session will help the Dermatologist understand the indications for the treatment of scarring alopecias and the approach to follicular rescue in scalp diseases that are thought to have only permanent damage. Faculty will discuss lichenplanopilaris, frontal fibrosing alopecia, traction alopecia, and central centrifugal cicatricial alopecia. Dermatoscopic and pathology clues to to viable hair growth in scarring scalp diseases will be covered. Familiar clinical treatments used in innovative combinations as well as ways to utilize newer treatments, such as: Platelet Rich Plasma, laser therapy, microneedling, and scalp hair restoration will be discussed.

Disclosures

  • Aguh, Crystal, MD: UCB – C(Fees); UpToDate, Inc – O(Fees);
  • Larrondo Galvez, Jorge Felipe: La Roche-Posay Laboratoire Pharmaceutique – C(Non-accredited CME Education Grant);
  • McMichael, Amy J., MD: Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding); Allergan, Inc. – C(H), I(OB); Anacor Pharmaceuticals, Inc. – A(H); Cassiopea S.p.A. – I(Grants/Research Funding); Concert Pharmaceuticals – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(OB); Incyte Corporation – C(H), I(Grants/Research Funding); Informa – O(OB); JAMA – O(NC); Johnson & Johnson Consumer Products Company – C(H); NAAF – A(NC); North American Hair Research Society – B(NC); Procter & Gamble Company – C(H), I(OB); Samumed, LLC – C(H); UpToDate, Inc – Speaker/Faculty Education(H);
  • Piliang, Melissa, MD: Eli Lilly and Company – I(NC); Pfizer Inc. – I(NC); Procter & Gamble Company – C(H);
  • Sadick, Neil S., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Allergan, Inc. – C(H), O(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H); Derm Advance – SH(SO); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Incyte Corporation – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Pfizer Inc. – I(Grants/Research Funding); Philips Healthcare – I(Grants/Research Funding); Prescriber's Choice – O(H); Regeneron – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Sol-Gel Technologies – I(Grants/Research Funding); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Shapiro, Jerry, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – A(H); Applied Biology – C(H); Bayer Consumer Healthcare Pharmaceuticals – C(NC); Bioniz Therapeutics – A(Fees); Cassiopea SpA – A(NC); Incyte Corporation – C(NC); Johnson & Johnson Consumer Products Company – C(H); L'OrĂ©al France – C(H); RegenLab – I(Grants/Research Funding); RepliCel Life Sciences – F(ST); Samumed, LLC – A(H);
  • Tosti, Antonella, MD: Aclaris Therapeutics, Inc. – A(H); Anacor Pharmaceuticals, Inc. – A(H); DS Laboratories – C(Fees); Fotofinder – C(EQ); Incyte Corporation – C(H); Kurt Wolff GmbH & Co. KG – A(H); Kythera – A(H); Meiji Seika Pharma Co., Ltd – A(H); MSD – SP(H); Novartis – A(H); PharmaDerm – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – C(H); Polichem SA – A(H); Procter & Gamble Company – A(H); Springer Science & Business Media – O(IP); Taylor & Francis – O(IP); topica – C(Fees); Valeant Pharmaceuticals International – C(Fees); Viamet Pharmaceuticals, Inc – A(H);
Schedule
Friday, March 1
9:00 AM
Dr. McMichael / Session Introduction
9:05 AM
Dr. Shapiro / Clinical Indications for Treatment of scarring alopecia
9:25 AM
Dr. Tosti / Dermatocopic Clues to predict treatment success in scarring alopecias
9:45 AM
Dr. Piliang / Pathologic Clues to predict treatment success in scarring alopecia
10:05 AM
Dr. Sadick / Platelet Rich Plasma in the treatment of Lichenplanopilaris and Frontal fibrosing alopecia
10:25 AM
Dr. Aguh / Plate Rich Plasma in the treatment of Central Centrifugal Cicatricial Alopecia
10:45 AM
Dr. McMichael / Successful Laser and medical treatment in traction alopecia and Central Centrifugal Cicatricial Alopecia
11:05 AM
Dr. Larrondo Galvez / Surgical Scalp Restoration in Scarring Alopecia:techniques and outcomes
11:25 AM
All faculty / Session Question and Answer
Event Details
  • Date
    Friday, March 1
  • Time
    9:00 AM - 12:00 PM
  • Location
    Salon G
  • CME Credits
    3.00
  • Type
    New
Directors/Co-Directors
  • Amy J. McMichael, MD, FAAD
Speakers
  • Antonella Tosti, MD - Handout
  • Crystal Aguh, MD, FAAD
  • Jerry Shapiro, MD, FAAD
  • Jorge Felipe Larrondo Galvez
  • Melissa Piliang, MD, FAAD
  • Neil S. Sadick, MD, FAAD